Blackstone, Carlyle Consider Bid for Novartis Generics Unit, Bloomberg Reports
February 01 2022 - 11:35AM
Dow Jones News
--Blackstone Inc. and Carlyle Group Inc. are in discussions to
team up to bid for Novartis AG's generic-drugs unit Sandoz, which
could be valued at $25 billion, Bloomberg reports, citing unnamed
sources.
--Advent International Corp., Hellman & Friedman LLC, KKR
& Co. and EQT AB are separately considering bids, Bloomberg
says.
--Some of the private equity companies could join up due to
Sandoz's size, according to Bloomberg.
--Novartis hasn't made a final decision on whether to spin off
or sell the unit, Bloomberg adds.
Full story: https://bloom.bg/3gfuZ8N
Write to Ed Frankl at edward.frankl@dowjones.com
(END) Dow Jones Newswires
February 01, 2022 11:20 ET (16:20 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024